Article info

Original research
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

Authors

  1. Correspondence to Dr Espen Basmo Ellingsen; espen.ellingsen{at}ultimovacs.com
View Full Text

Citation

Ellingsen EB, Aamdal E, Guren T, et al
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

Publication history

  • Accepted April 14, 2022
  • First published May 25, 2022.
Online issue publication 
May 25, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.